Erik Anders Kronström
Chief Operating Officer bij INFANT BACTERIAL THERAPEUTICS AB
Vermogen: 83 751 $ op 31-03-2024
Profiel
Erik Anders Kronström is currently the Chief Operating Officer at Infant Bacterial Therapeutics AB since 2018.
Previously, he worked as the Chief Executive Officer at Biosergen AS.
He holds an MBA from Warwick Business School and a graduate degree from the Royal Institute of Technology.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 26-05-2023 | 11 194 ( 0.09% ) | 83 751 $ | 31-03-2024 |
Actieve functies van Erik Anders Kronström
| Bedrijven | Functie | Begin |
|---|---|---|
| INFANT BACTERIAL THERAPEUTICS AB | Chief Operating Officer | 01-01-2018 |
Eerdere bekende functies van Erik Anders Kronström
| Bedrijven | Functie | Einde |
|---|---|---|
Biosergen AS
 Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway. | Chief Executive Officer | - |
Opleiding van Erik Anders Kronström
| Warwick Business School | Masters Business Admin |
| Royal Institute of Technology | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| INFANT BACTERIAL THERAPEUTICS AB | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Biosergen AS
Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway. | Health Technology |
